Asthma Clinical Trial
— CASCADEOfficial title:
A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults With Inadequately Controlled Asthma on Inhaled Corticosteroids and at Least One Additional Asthma Controller (CASCADE)
Verified date | February 2022 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A phase 2, multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in adults with inadequately controlled asthma.
Status | Completed |
Enrollment | 116 |
Est. completion date | November 16, 2020 |
Est. primary completion date | November 16, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Principal Inclusion Criteria: - Subject must be 18 to 75 years of age. - Documented physician-diagnosed asthma for at least 12 months. - Subjects who have received a physician- prescribed asthma controller medication with medium or high dose ICS for at least 12 months; must be stable for at least 3 months prior to screening visit. - At least one additional maintenance asthma controller medication is required according to standard practice of care and must be documented for at least 3 months. - At enrolment, the subject must have a predicted normal value for the morning pre-bronchodilator FEV1>50% and more than 1L. - Evidence of asthma as documented by reversibility of FEV1 =12% and =200 mL in the previous 12 months prior to screening, or during the screening period prior to randomization. - ACQ-6 score = 1.5 during the screening period prior to randomization. Principal Exclusion Criteria: - Any clinically important pulmonary disease other than asthma. - History of cancer. - Hospitalization or required OCS for asthma exacerbation within 6 weeks of enrolment or >3 exacerbations requiring OCS or hospitalization in the year prior to visit 1 or who had been intubated or admitted to ICU for asthma exacerbation in the year prior to enrolment. - History of a clinically significant infection, including upper (URTI) or lower respiratory tract infection (LRTI), requiring treatment with antibiotics or antiviral medications finalized <2 weeks before visit 1 or during the run-in period. - Current smokers or subjects with smoking history =10 pack-yrs, including e-cigarettes. Former smokers with a smoking history of <10 pack-yrs must have stopped for at least 6 months prior to visit 1, including e-cigarette use. - History of chronic alcohol or drug abuse within 12 months prior to visit 1. - Tuberculosis requiring treatment within 12 months prior to visit 1. - History of known immunodeficiency disorder including a positive HIV test at visit 1, or the subject is taking antiretroviral medications as determined by medical history and/or subject's verbal report. - History of anaphylaxis or documented immune complex disease (type III hypersensitivity reactions) following any biologic therapy Subject randomized in a previous Tezepelumab study or in a current study with another investigational product. - Pregnant, breastfeeding or lactating women. |
Country | Name | City | State |
---|---|---|---|
Canada | Research Site | Calgary | Alberta |
Canada | Research Site | Hamilton | Ontario |
Canada | Research Site | Montreal | Quebec |
Canada | Research Site | Ottawa | Ontario |
Canada | Research Site | Quebec | |
Canada | Research Site | Vancouver | British Columbia |
Denmark | Research Site | Aarhus N | |
Denmark | Research Site | Ålborg | |
Denmark | Research Site | Hvidovre | |
Denmark | Research Site | København NV | |
Denmark | Research Site | Naestved | |
Denmark | Research Site | Odense C | |
Denmark | Research Site | Vejle | |
Germany | Research Site | Frankfurt | |
Germany | Research Site | Frankfurt/Main | |
Germany | Research Site | Grosshansdorf | |
Germany | Research Site | Landsberg | |
United Kingdom | Research Site | Cambridge | |
United Kingdom | Research Site | Headington | |
United Kingdom | Research Site | Leicester | |
United Kingdom | Research Site | London | |
United Kingdom | Research Site | Nottingham | |
United Kingdom | Research Site | Wythenshawe | |
United States | Research Site | Boston | Massachusetts |
United States | Research Site | Denver | Colorado |
United States | Research Site | Galveston | Texas |
United States | Research Site | New Haven | Connecticut |
United States | Research Site | Pittsburgh | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca | Amgen |
United States, Canada, Denmark, Germany, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Airway Submucosal Inflammatory Cells Ratio Change From Baseline to EOT. | The change from baseline to end of treatment (EOT) expressed as a ratio i.e. (EOT/baseline) in numbers of each of the airway submucosal inflammatory cells, determined by microscopic evaluation of bronchoscopic biopsies. | First dose of investigational product to end of treatment (EOT) at Week 28 (or up to Week 48 due to COVID19 pandemic). | |
Secondary | Reticular Basement Membrane (RBM) Thickness Ratio Change From Baseline to EOT. | The change from baseline to EOT expressed as a ratio i.e. (EOT/baseline) in RBM thickness, determined by microscopic evaluation of bronchoscopic biopsies. | First dose of investigational product to end of treatment (EOT) at Week 28 (or up to Week 48 due to COVID19 pandemic). | |
Secondary | Percent (%) Airway Epithelial Integrity Ratio Change From Baseline to EOT. | The change from baseline to EOT expressed as a ratio i.e. (EOT/baseline) in % airway epithelial, determined by microscopic evaluation of bronchoscopic biopsies. | First dose of investigational product to end of treatment (EOT) at Week 28 (or up to Week 48 due to COVID19 pandemic). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|